Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $263.17, for a total value of $2,631,700.00. Following the sale, the chief executive officer now directly owns 470,174 shares in the company, valued at approximately $123,735,692. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.59% on Friday, hitting $262.03. 297,243 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a one year low of $30.55 and a one year high of $497.00. The stock has a 50-day moving average of $310.9 and a 200-day moving average of $216.9. The company’s market cap is $5.115 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Friday, March 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.06. During the same quarter in the previous year, the company posted ($2.02) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-2.97 earnings per share for the current fiscal year.

A number of research firms have recently commented on ICPT. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, April 14th. Five investment analysts have rated the stock with a buy rating, Intercept Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $578.00.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.